Panel Discussion: Understanding How to Best Conduct Long-Term Safety Monitoring

Time: 12:30 pm
day: Day Two


• Assessing the current FDA guidelines

• Reviewing how effective long-term follow up protocol is at truly understanding the long-term safety of AAV gene therapies

• Strategize additional monitoring to better inform the long-term safety profile